- Home
- NXDT vs APLT Comparison
NXDT vs APLT Comparison
Compare NXDT & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXDT
- APLT
- Stock Information
- Founded
- NXDT 2012
- APLT 2016
- Country
- NXDT United States
- APLT United States
- Employees
- NXDT N/A
- APLT N/A
- Industry
- NXDT Investment Managers
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- NXDT Finance
- APLT Health Care
- Exchange
- NXDT Nasdaq
- APLT Nasdaq
- Market Cap
- NXDT 223.1M
- APLT 178.6M
- IPO Year
- NXDT N/A
- APLT 2019
- Fundamental
- Price
- NXDT $3.52
- APLT $1.05
- Analyst Decision
- NXDT
- APLT Buy
- Analyst Count
- NXDT 0
- APLT 5
- Target Price
- NXDT N/A
- APLT $4.13
- AVG Volume (30 Days)
- NXDT 133.6K
- APLT 11.8M
- Earning Date
- NXDT 01-01-0001
- APLT 11-06-2025
- Dividend Yield
- NXDT 9.66%
- APLT N/A
- EPS Growth
- NXDT N/A
- APLT N/A
- EPS
- NXDT 0.99
- APLT N/A
- Revenue
- NXDT N/A
- APLT $121,000.00
- Revenue This Year
- NXDT N/A
- APLT N/A
- Revenue Next Year
- NXDT N/A
- APLT $5,931.24
- P/E Ratio
- NXDT $6.41
- APLT N/A
- Revenue Growth
- NXDT N/A
- APLT N/A
- 52 Week Low
- NXDT $5.89
- APLT $0.30
- 52 Week High
- NXDT $13.07
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- NXDT 32.42
- APLT 66.45
- Support Level
- NXDT $3.38
- APLT $0.56
- Resistance Level
- NXDT $4.04
- APLT $1.32
- Average True Range (ATR)
- NXDT 0.16
- APLT 0.17
- MACD
- NXDT -0.04
- APLT 0.05
- Stochastic Oscillator
- NXDT 7.06
- APLT 73.60
About NXDT NexPoint Diversified Real Estate Trust
NexPoint Diversified Real Estate Trust is a publicly traded REIT focused on opportunistic real estate investments in the United States. Their portfolio includes diverse commercial properties and investments across various real estate sectors and capital structures. The revenue sources of the company include rental income from office and retail properties, interest income from debt investments, dividend income from equity investments, and other ancillary income from tenants. The company operates through its operating partnership and wholly owned subsidiaries.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.